| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 17, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 17, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's we
SAN RAFAEL, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2024 after the close of trading on Monday, October 28, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the event will be available in the "Investors" section of the Company's website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)
SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC ("Bionic P&O"), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor. Ekso Indego Personal is a wearable lower extremity powered exoskeleton that enables certain individuals living with spinal cord injuries ("SCIs") with the ability to stand and walk independently. It is the only known portable exoskeleton device to offer a modular quick connect design, wh
SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor
SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's we
11-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
EFFECT - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
S-3 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)
SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)
Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie
Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti
RICHMOND, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Jerome Wong as Interim Chief Financial Officer following the departure of current CFO Jack Glenn. Mr. Glenn resigned effective June 17, 2022 to pursue a new position at another public company. Mr. Glenn's resignation is not the result of any dispute or disagreement with the Company including any matters relating to the Company's accounting practices or financial reporting. "I am excited that Jerome has accepted the Interim CFO role after having served as our Controll